SEC Form 4 · accession 0001610717-26-000302
Aligos Therapeutics, Inc. · ALGS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
James Paul Scopa
Director
Period of report
Jun 25, 2026
Accepted (ET)
Jun 29, 2026 · 4:36 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001799448
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $5.50 | Jun 25, 2026 | A | 5,860 | A | — | Jun 25, 2036 | Common Stock | 5,860 | 5,860 | D |
Explanation of responses
- F1The shares subject to the option will vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of the first anniversary of the grant date or immediately prior to the annual meeting in 2027 of the Issuer's stockholders, subject to continuous service to the Issuer through such vesting date.